164P Preliminary results from a phase I/II study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors

Monica Sharma, Richard D. Carvajal, Glenn J. Hanna, Yoon‐Koo Kang, J. Lee, K.W. Lee, B.T. Li, Kathleen N. Moore, Mark D. Pegram, Drew Rasco, Alexander I. Spira, Dee Dee Wang, Benjamin A. Weinberg, Marta M. Alonso, Ling Fang, Amreen Husain, Marcin Kowanetz, EA Perez, Ecaterina I. Dumbrava